Polymeric STING Pro-agonists for Tumor-Specific Sonodynamic Immunotherapy.

Area of Science:

• Biomedical Engineering
• Cancer Research
• Immunotherapy

Background:

• Combination immunotherapy faces challenges in tumor specificity and immune-related adverse events (irAEs).
• Targeted drug delivery and controlled activation are crucial for effective cancer treatment.
• The tumor microenvironment (TME) presents unique conditions that can be exploited for therapeutic benefit.

Purpose of the Study:

• To develop a novel sono-immunotherapeutic agent for enhanced cancer treatment.
• To achieve spatiotemporal control over drug release and immune activation within the TME.
• To overcome the limitations of current immunotherapies by improving tumor specificity and reducing off-target effects.

Main Methods:

• Development of polymeric STING pro-agonists (PSPA) integrating sonosensitizers and STING agonists (MSA-2) via glutathione (GSH)-activatable linkers.
• Activation of PSPA using sono-irradiation to generate singlet oxygen (¹O₂) and induce immunogenic cell death (ICD).
• Targeted release of MSA-2 within the TME, facilitated by high GSH levels, and subsequent STING pathway activation.

Main Results:

• Sono-irradiation of PSPA generated ¹O₂, inducing ICD in malignant tumor cells.
• GSH-triggered release of MSA-2 in the TME minimized off-target side effects.
• STING pathway activation elevated interferon-β levels, synergizing with sonodynamic therapy (SDT) to enhance anti-tumor efficacy.

Conclusions:

• PSPA offers a universal approach for spatiotemporal regulation of cancer sono-immunotherapy.
• This strategy enhances anti-tumor immune responses through targeted ICD and STING activation.
• The developed system demonstrates potential for improved cancer treatment with reduced toxicity.